Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB08 in Psoriasis Vulgaris
NCT02796053Phase 2Completed
- Sponsor
- TheraMAB
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Psoriasis vulgaris (PV) comparing Placebo with TAB08 Dose 1 (2 arms). Primary endpoints: Change of T-lymphocytes subsets in absolute count at 12 weeks, Change of T-lymphocytes subsets in percent at 12 weeks and 2 more. Started Apr 2016; status: completed.
02
Drugs
theralizumab
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02796053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796053.